NanoViricides, Inc. (NNVC)
After hours:
| Previous Close | 2.2300 |
| Open | 2.2200 |
| Bid | 2.0200 x 3100 |
| Ask | 2.1700 x 800 |
| Day's Range | 2.0000 - 2.2500 |
| 52 Week Range | 1.0000 - 2.2900 |
| Volume | |
| Avg. Volume | 104,865 |
| Market Cap | 24.383M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8000 |
| Earnings Date | May 16, 2024 - May 17, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.50 |
ACCESSWIRENanoViricides Has Filed its Quarterly Report
NV-387 Advancing to Phase II Clinical Trial for the Treatment of RSV Infection SHELTON, CT / ACCESSWIRE / May 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that ...
- ACCESSWIRE
A Novel Broad-Spectrum Antiviral with Activity Against RSV
Complete Survival of Animals Lethally Infected into Lungs with RSV Achieved Upon NV-387 Oral Treatment SHELTON, CT / ACCESSWIRE / May 14, 2024 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, ...
- ACCESSWIRE
NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City
SHELTON, CT / ACCESSWIRE / May 10, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's President and Executive Chairman, ...
